Q1 FY27 Results: Revenue up 269% YoY standalone, PAT nearly flat
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Microcap 250 and 2.9 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Genpharmasec posted Q1 FY27 (quarter ended June 30, 2026) standalone revenue of Rs. 4,474.44 lakhs, up about 269% from Rs. 1,211.32 lakhs in Q1 FY26. Profit after tax was nearly flat at Rs. 156.96 lakhs vs Rs. 155.52 lakhs. Consolidated revenue rose to Rs. 4,971.03 lakhs but consolidated PAT fell sharply to Rs. 22.60 lakhs from Rs. 117.81 lakhs. Auditor changed to Bilimoria Mehta and Co from prior year auditor Abhishek S Tiwari and Associates.
Strong revenue growth but margin pressure at consolidated level. PAT flat standalone, down sharply consolidated. New auditor noted.